Kiadis Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Kiadis Pharma's estimated annual revenue is currently $10.5M per year.
- Kiadis Pharma's estimated revenue per employee is $155,000
Employee Data
- Kiadis Pharma has 68 Employees.
- Kiadis Pharma grew their employee count by -36% last year.
Kiadis Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $10.4M | 67 | -6% | N/A | N/A |
#2 | $4.3M | 28 | 40% | N/A | N/A |
#3 | $2.3M | 15 | 15% | N/A | N/A |
#4 | $1.1M | 7 | 17% | N/A | N/A |
#5 | $3.7M | 24 | -11% | N/A | N/A |
#6 | $1.4M | 9 | 50% | N/A | N/A |
#7 | $49.9M | 322 | -17% | N/A | N/A |
#8 | $1.1M | 7 | 17% | N/A | N/A |
#9 | $2.3M | 15 | -6% | N/A | N/A |
#10 | $10.5M | 68 | -36% | N/A | N/A |
What Is Kiadis Pharma?
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Kiadis Pharma is committed to developing innovative and potentially life'saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.
keywords:N/A
N/A
Total Funding
68
Number of Employees
$10.5M
Revenue (est)
-36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kiadis Pharma News
Kiadis Pharma; Cytovia Therapeutics; Nkarta, Inc; Fate Therapeutics; EMERcell; Glycostem; Phio Pharmaceuticals, Innate Pharma, Inc...
... Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and Medexus Pharma, Inc. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics...
Bluebird Bio; Novartis; Kiadis Pharma; Acceleron Pharma. Alpha Thalassemia Market Breakdown by Type: Iron Chelating Drugs; Gene Therapy.
Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be held at 15:00 CEST on 28 June 2021. Pursuant to tempor ...
Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders ("AGM”) will be held at 15:00 CEST on 28 June 2021. ...
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $19.9M | 68 | -16% | N/A |
#2 | $12.9M | 68 | 79% | N/A |
#3 | $8.6M | 68 | 119% | N/A |
#4 | $13.9M | 68 | 33% | N/A |
#5 | $7.5M | 69 | 11% | N/A |